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ABSTRACT

~

Purpose: To determine the validity of main pulmonary artery diameter (MPAD)
as a marker of pulmonary hypertension in scleroderma patients with and without
interstitial lung disease (llO).
Materials and Methods: We cross-referenced the radiologic database with
medical records to identify patients with both computed tomography (CT) scans
of the chest and right-heart catheterization separated by no more than six
months. Computed tomography scans were reviewed to determine MPAD and
extent of IlO for each patient. Ground glass opacity and fibrosis were individually
scored by a single thoracic radiologist on a five-point scale. The same radiologist
also determined the quality of delineation for the great vessels. MPAD was
calculated based on the average of measurements taken from two separate
observers. Mean pulmonary arterial pressures (mPAP) were determined by
RHC. Patients were divided into either group A (n = 20) or group B (n = 27)
based on the absence or presence of interstitial fibrosis respectively. Patients
with available data from pulmonary function tests (PFTs) were divided into those
with FVC > 70% predicted (Group C) and those with FVC < 70% predicted
(Group D). Groups were compared using either the Student t test or MannWhitney U test depending on the distribution of each variable under
consideration. Either the Pearson correlation coefficient or the Spearman rankcorrelation coefficient was calculated for each group to evaluate the relationship
between MPAD and mPAP.
Results: Groups A and B were similar with regard to MPAD (p = 0.28) and
mPAP (p = 0.34) upon Mann-Whitney U testing. MPAD was strongly correlated
with mPAP in both Group A (r = 0.68, P = 0.001) and Group B (r = 0.70, P <
0.0001). The correlation between MPAD and mPAP in Group C (r = 0.69, P =
0.002) was substantially higher than that in Group 0 (r = 0.42, P = 0.11).
Conclusion: In our patient sample with scleroderma, MPAD is strongly
correlated with mPAP and may indicate the development of pulmonary
hypertension regardless of the presence of mild to moderate interstitial fibrosis.
An increase in the severity of restrictive lung disease as measured by FVC
appears to attenuate the correlation between MPAO and mPAP.

CHAPTER 1
INTRODUCTION

Scleroderma refers to a fibrotic thickening of the skin that frequently
becomes clinically apparent in several different pathologic states involving
connective tissue derangements of production and organization. Though strictly
only a symptom, the use of this term has, over time, become synonymous with
the disease known as systemic sclerosis (SSc). Regardless of how one chooses
to use the label "scleroderma", the fibrotic mechanism underlying this finding may
lead to other systemic manifestations that overlap across the various connective
tissue diseases. As a model illness for which scleroderma is the most clinically
evident symptom, SSe can involve many organs throughout the body and show
marked heterogeneity in the time course of disease progression.
Concerning SSe, progressive pulmonary dysfunction has become the
primary concern, following the release of ACE inhibitors for scleroderma renal
crisis, of those investigating mortality linked to this disease. Indeed, pulmonary
complications have steadily replaced scleroderma renal crisis as the primary
cause of SSc-related death with approximately 500/0 of mortalities resulting from
an associated decline in lung function [1]. Current research is focused on
identifying underlying visceral involvement in the early stages so that treatment
may be initiated in a timely fashion. Pulmonary involvement in SSc ranges from
minor parenchymal fibrosis to severe pulmonary hypertension (PH). To
complicate matters, PH in SSc can result from the progression of interstitial lung
disease (ILD) or develop as an isolated pulmonary arterial hypertension (PAH),
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itself a major mortality factor independent of ILD extent [2]. The clinical
evaluation of pulmonary hypertension has proven challenging in the SSc
population with 20% of connective tissue disease patients having undiagnosed
severe PAH [3] and 14% of SSc patients developing severe PH in the face of
initial echocardiographic evidence to the contrary [4]. With regard to screening,
both the invasive nature of right heart catheterization (RHC) and the lack of
echocardiographic sensitivity have led to an exploration of alternative methods
for establishing the diagnosis of PH in general populations at risk of such
involvement [5-10]. Computed tomography (CT or CAT) has been investigated
as a potential screening device capable of simultaneously assessing the degree
of parenchymal lung disease and the level of pulmonary arterial pressure
(PAP)[6]. Many studies support the use of chest CT in predicting PH [5-9] with
some reporting correlation coefficients as high as 0.83 between main pulmonary
artery diameter (MPAD) measurements and PAP [8]. With continued research in
this field, it has become increasingly evident that this correlation may be
substantially altered by the presence of specific comorbidities. For example,
pulmonary fibrosis has recently been found to substantially alter the correlation
between MPAD and PAP [11, 12].
In light of the recent identification of pulmonary fibrosis as a complicating
factor and when considering the heterogeneity of clinical presentation in SSc, it is
necessary that the relationship between MPAD and PAP be closely examined in
the scleroderma population. Furthermore, all but one previous study [13] have
evaluated the utility of the MPAD measurement in mixed populations comprised
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of very few SSc patients. This study will be the first to analyze the correlation
between MPAD and PAP using a variety of chest CT protocols to access
pulmonary involvement in a sample of scleroderma patients. In acknowledgment
of the fact that a large number of cases of PAH occur in SSc patients with little to
no fibrotic lung involvement and realizing that pulmonary fibrosis, when present,
benefits most from early intervention, this study will focus on examining the
correlation between MPAD and PAP in patients without the presence of fibrosis
on chest CT as well as those with mild to moderate lung disease.
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CHAPTER 2
REVIEW OF LITERATURE

2.1 SYSTEMIC SCLEROSIS OVERVIEW
Systemic Sclerosis (SSc) is an autoimmune disease characterized by
widespread mesenchymal cell activation that results in substantial extracellular
matrix deposition and fibrosis throughout the body [14]. This disease is
notoriously complex with an etiology that remains unclear. Dermal thickening,
a.k.a. scleroderma, is seen in the vast majority of SSc cases. Visceral effects
are also common and such involvement can progress on a subclinical level for
many years [15]. Historically, visceral involvement in SSc has centered around
the heart, lungs, kidneys, and gastrointestinal tract. Renal complications account
for the majority of SSc-related deaths in the literature predating the release of
ACE inhibitors [16-18]. This paradigm has since shifted with pulmonary
complications now accounting for approximately 500/0 of deaths resulting from
SSc [1]. With a wide range of potential organ involvement, patient prognosis in
SSc is difficult to predict. Therefore, a significant body of literature has been
devoted to arranging patients into symptomatically uniform groups for the
purpose of establishing accurate prognostic models.
In order to standardize the classification of SSc patients for research
purposes, the American College of Rheumatology (ACR) adopted several criteria
in 1980 that address the most common manifestations of this disease [19].
Using this system, the classification of suspected SSc cases depends on the
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identification of either one major criterion or two minor criteria from a list of
multiple disease characteristics. This classification allows patients being
evaluated for SSc to be listed as either "definite" or "probable" regarding their
disease status and comparisons between patient populations in the literature can
be made using this system. A subclassification scheme has been proposed [14]
based on the extent of cutaneous involvement and is commonly used in the
clinic. The two main subtypes of SSc are limited cutaneous scleroderma (lcSSc)
and diffuse cutaneous scleroderma (dcSSc). This model has been shown to
define groups with significantly different prognoses. The study that led to this
classification scheme incorporated data from SSc patients in whom twelve year
survival for diffuse and limited scleroderma was 15% and 500/0 respectively [20].
More recently, Ferri et al. [15] have demonstrated a similar trend, though
somewhat less in magnitude. In their study of Italian patients, the authors report
a ten year survival of 750/0 in IcSSc, a significant difference from the 530/0 survival
seen in the diffuse subtype [15]. Other factors such as seriologic profile and
organ involvement, especially the lung, may also be associated with SSc
cutaneous subtype [15, 17,20-22].
As mentioned earlier, pulmonary involvement has become the primary
cause of death in SSc and much effort has been devoted to uncovering the
nature of this involvement across different scleroderma subtypes. The remainder
of this review will be largely devoted to a discussion of the pulmonary
complications seen in SSc. The use of computed tomography (CT) in this
population as a non-invasive tool, potentially capable of assessing the degree of
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interstitial lung disease (ILD) in a given patient as well as identifying those
subjects who may benefit from further evaluation for pulmonary hypertension
(PH), will also be reviewed.
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2.2 PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS
2.2.1 Interstitial Lung Disease
Bounded on either side by basement membrane, the interstitial
compartment of the lung may become pathologically altered as the result of over
150 different stimuli [23]. Interstitial lung disease is the name given to the wide
range of such alterations originating within this compartment. Lung biopsy,
bronchoalveolar lavage (BAL), pulmonary function testing (PFT), and CT are all
methods currently utilized by clinicians to confirm the presence of ILD, with
biopsy and subsequent pathologic evaluation being the gold standard for this
diagnosis. Various histological patterns exist depending on the degree and
distribution of inflammatory cell infiltration and fibrosis throughout the interstitium.
Though originally considered to exclusively resemble a histopathological
type of ILD known as usual interstitial pneumonia (UIP) [24], it has since been
shown that pulmonary interstitial involvement in SSc frequently incorporates
features of non-specific interstitial pneumonia (NSIP) [25]. In idiopathic
pulmonary fibrosis (IPF), a disease classically characterized by the former
histopathological pattern, patients with UIP demonstrate diminished survival
when compared to those with NSIP [26]. In addition, a better prognosis has been
linked with SSc-associated ILD in past studies [27,28] when compared to
patients with IPF. Therefore" it may be expected that
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have a worse prognosis than those with a predominately NSIP pattern of ILD.
Bouros et al. [29] have demonstrated, however, that 1O-year survival in SSc
patients with NSIP did not differ significantly from those with UIP upon
retrospective study. In fact, they found that survival depended on initial
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physiologic measures taken from PFTs rather than histopathology [29]. As this
finding contradicts that seen in IPF [26], the prognostic significance of histological
typing in SSc-related ILD remains uncertain.
In contrast to biopsy and pathologic examination, pulmonary function
testing is a non-invasive and easily performed clinical assessment regularly used
to detect the presence of ILD in SSc patients as well as monitor disease
progression. Forced vital capacity (FVC) is one measure derived from PFTs that
is widely used to evaluate the restrictive lung defect generated by SSc-related
ILD. In a study by Steen et al. [30], lower values of FVC were associated with a
decreased cumulative 1O-year survival rate. Risk factors for severe restrictive
lung disease in SSc include African American race and the diffuse cutaneous
subtype [30]. Such factors may be related to a greater extent of inflammatory
and fibrotic lung involvement in as much as FVC correlates with the severity of
interstitial disease. Yet, as discussed below, FVC is only weakly associated with
the extent of disease on CT and may not provide an accurate estimate of total
interstitial lung involvement in SSc.

2.2.2 Pulmonary Hypertension
Pulmonary hypertension (PH) is a disorder characterized by elevated
pulmonary arterial pressure (PAP) often leading to dyspnea and eventual right
heart failure. In SSc, PH can result from the compression of capillaries due to
progressive ILD, develop as an isolated pulmonary arterial hypertension (PAH) in
which proliferation of the vascular wall leads to occlusion, or emerge as a
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combination of these two processes. In a Canadian multicenter study [31]
where 290/0 of patients were found to have elevated PAP, 54.8% had isolated
PAH while 29.8% had PH secondary to ILD. In contrast, Launay et al. [32] found
a prevalence of 18.3% for moderate to severe PH in SSc, regardless of the
presence or absence of significant restrictive lung disease defined as an FVC <
70% predicted. Risk factors for the development of PH in SSc include Raynaud's
phenomenon that precedes skin manifestations by at least 3 years, FVC < 80%
predicted, and fibrosis on high resolution chest CT [33]. The limited cutaneous
subtype of SSc is associated with rapid progression of PH [21].
The screening of SSc patients for PH is an essential practice. Indeed,
there is a propensity for elevated PAP to go unnoticed for many years in this
population. For instance, Wigley et al. [3] uncovered a large group of patients,
13.3% of those studied, from 50 separate community rheumatology clinics with
PAH that had gone previously undetected. Perhaps more importantly, it has
been shown in dcSSc-related ILD that PAH is an independent predictor of
mortality [2]. While PFTs are often ordered when screening for PH,
echocardiography and CT may be more suitable for this purpose. Carbon
monoxide diffusing capacity (OLeo) has been explored as a possible functional
correlate of PH [34-36] with conflicting results. A study by Mukerjee et al. [34]
found a very weak correlation between OLeo and PAP. The tricuspid gradient
(TG) on echocardiography exhibited a much stronger correlation with PAP [34]
and has recently been incorporated into a composite index along with the CTderived measurement of main pulmonary artery diameter (MPAO) to screen for
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PH [13]. Much of the remainder of this review will be devoted to a discussion
concerning the utility of CT in evaluating PH.

2.2.3 Computed Tomography
In the SSc population, CT is widely employed as part of a complete
workup of scleroderma lung disease. Aside from biopsy, computed tomography
is the only means by which clinicians can directly visualize the inflammation and
fibrosis within the lung. It is now standard practice for SSc patients to be
evaluated using CT if dyspnea or abnormal PFTs are present. High resolution
computed tomography (HRCT) has replaced conventional CT protocols as the
gold standard for diagnosis of SSc-related IlO. The main difference between
HRCT and conventional CT is the thickness of the slice of tissue being imaged
by the scanner [37]. Increased distance between slices is also typical of HRCT
protocols, making this imaging technique most suitable for diffuse lung disease
such as that seen in SSc [37]. Multiple protocols [11, 38, 39] exist to quantify the
extent of IlO on chest CT images. In general, most protocols grade interstitial
involvement based on the amount of ground glass opacity (GGO), reticulation,
and/or honeycombing appearing throughout the lung. Pulmonary function has
been shown to correlate weakly with the extent of abnormality on chest CT [3941]. This finding suggests that PFTs alone are insufficient for monitoring the
natural course of ILO in SSc. Thus, HRCT is essential not only for the evaluation
of early disease, but also for tracking disease progression and response to
treatment.
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Aside from the utility of CT in detecting underlying ILD, this form of
imaging has also been the topic of much research [5, 7, 8, 10-12,42] regarding
the evaluation of PH. The pulmonary artery is easily visualized as it passes over
the base of the heart on axial CT images and the measurement of MPAD has
been found to correlate nicely with PAP [5, 7, 8]. Many of the studies which have
examined this relationship have done so in groups of patients with an array of
cardiopulmonary diagnoses. Only two studies [13, 36] have looked at the
correlation between MPAD and measures of PH in SSc. While Pandey et al. [36]
found MPAD to correlate with peak PAP on echocardiography, they concluded
that CT-derived fibrosis score was a stronger determinant of PAP. Condliffe et
al. [13] evaluated the relationship between MPAD and PAP measured by right
heart catheterization in SSc and reported a correlation coefficient of 0.35. This
correlation was stronger (r = 0.57) when excluding those patients with significant
ILD defined as FVC < 700/0 predicted or extent of lung involvement > 20% on
chest CT [13]. Similarly, prior studies in IPF [11] and generalized populations
with pulmonary disease [12, 42] have suggested that pulmonary fibrosis
attenuates the correlation between MPAD and PAP. The methods used by
Condliffe et al. [13] to exclude patients with significant ILD, however, leave
several questions unanswered regarding this observation. For instance, do PFT
results and disease extent on HRCT equally affect the correlation between
MPAD and PAP? Also, do patients with mild to moderate ILD show the same
attenuation in the correlation coefficient? Continued research in this area may
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reveal the answer to these questions and help further identify the role of CT in
the assessment on SSe-related lung disease.
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CHAPTER 3

MANUSCRIPT

Relationship of Main Pulmonary Artery Diameter to Pulmonary Arterial
Pressure in Scleroderma Patients with and without Mild to Moderate
Interstitial Fibrosis

Robert K. McCall, BS; James G. Ravenel, MD; Paul J Nietert, PhD; Aleksandra
Granath, MD; Marcy B. Bolster, MD; Richard M. Silver, MD
Division of Rheumatology, Department of Medicine
Division of Biostatistics and Epidemiology, Department of Medicine
Department of Radiology
Medical University of South Carolina

3.1 ABSTRACT

Purpose: To determine the validity of main pulmonary artery diameter (MPAD)
as a marker of pulmonary hypertension in scleroderma patients with and without
interstitial lung disease (llO).
Materials and Methods: We cross-referenced the radiologic database with
medical records to identify patients with both computed tomography (CT) scans
of the chest and right-heart catheterization separated by no more than six
months. Computed tomography scans were reviewed to determine MPAD and
extent of IlD for each patient. Ground glass opacity and fibrosis were individually
scored by a single thoracic radiologist on a five-point scale. The same radiologist
also determined the quality of delineation for the great vessels. MPAO was
calculated based on the average of measurements taken from two separate
observers. Mean pulmonary arterial pressures (mPAP) were determined by
RHC. Patients were divided into either group A (n =20) or group B (n =27)
based on the absence or presence of interstitial fibrosis respectively. Patients
with available data from pulmonary function tests (PFTs) were divided into those
with FVC > 700/0 predicted (Group C) and those with FVC < 70% predicted
(Group D). Groups were compared using either the Student t test or MannWhitney U test depending on the distribution of each variable under
consideration. Either the Pearson correlation coefficient or the Spearman rankcorrelation coefficient was calculated for each group to evaluate the relationship
between MPAD and mPAP.
Results: Groups A and B were similar with regard to MPAO (p = 0.28) and
mPAP (p =0.34) upon Mann-Whitney U testing. MPAD was strongly correlated
with mPAP in both Group A (r =0.68, P =0.001) and Group B (r =0.70, P <
0.0001). The correlation between MPAD and mPAP in Group C (r = 0.69, P =
0.002) was substantially higher than that in Group D (r =0.42, P =0.11).
Conclusion: In our patient sample with scleroderma, MPAD is strongly
correlated with mPAP and may indicate the development of pulmonary
hypertension regardless of the presence of mild to moderate interstitial fibrosis.
An increase in the severity of restrictive lung disease as measured by FVC
appears to attenuate the correlation between MPAD and mPAP.
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3.2 INTRODUCTION
Progressive pulmonary dysfunction has become the primary concern,
following the release of ACE inhibitors for scleroderma renal crisis, of those
investigating mortality linked to Systemic Sclerosis (SSc). Indeed, pulmonary
complications have steadily replaced scleroderma renal crisis as the primary
cause of SSc-related death with approximately 50% of mortalities resulting from
an associated decline in lung function [1]. Pulmonary involvement in SSc ranges
from minor parenchymal fibrosis to severe pulmonary hypertension (PH). To
complicate matters, PH in SSc can result from the progression of interstitial lung
disease (ILD) or develop as an isolated pulmonary arterial hypertension (PAH),
itself a major mortality factor independent of ILD extent [2]. The clinical
evaluation of pulmonary hypertension has proven challenging in the SSc
population with 20% of connective tissue disease patients having undiagnosed
severe PAH [3] and 140/0 of SSc patients developing severe PH in the face of
initial echocardiographic evidence to the contrary [4].
With regard to screening, both the invasive nature of right heart
catheterization (RHC) and the lack of echocardiographic sensitivity have led to
an exploration of alternative methods for establishing the diagnosis of PH in
general populations at risk of such involvement [5-10]. Computed tomography
(CT or CAT) has been investigated as a potential screening device capable of
simultaneously assessing the degree of parenchymal lung disease and the level
of pulmonary arterial pressure (PAP) [6]. Many studies support the use of chest
CT in predicting PH [5-9] with some reporting correlation coefficients as high as
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0.83 between main pulmonary artery diameter (MPAD) measurements and PAP
[8]. With continued research in this field, it has become increasingly evident that
this correlation may be substantially altered by the presence of specific
comorbidities. For example, pulmonary fibrosis has recently been found to
substantially alter the correlation between MPAD and PAP [11, 12].
In light of the recent identification of pulmonary fibrosis as a complicating
factor and when considering the heterogeneity of clinical presentation in SSc, it is
necessary that the relationship between MPAD and PAP be closely examined in
the scleroderma population. Furthermore, all but one previous study [13] have
evaluated the utility of the MPAD measurement in mixed populations comprised
of very few SSc patients. This study will be the first to analyze the correlation
between MPAD and PAP using a variety of chest CT protocols to access
pulmonary involvement in a sample of scleroderma patients. In acknowledgment
of the fact that a large number of cases of PAH occur in SSc patients with little to
no fibrotic lung involvement and realizing that pulmonary fibrosis, when present,
benefits most from early intervention, this study will focus on examining the
correlation between MPAD and PAP in patients without the presence of fibrosis
on chest CT as well as those with mild to moderate lung disease.
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3.3 METHODS
3.3.1 Patient Selection
This study was a retrospective review of patient records and chest CT
images contained electronically at our institution. Institutional review board
approval as well as an informed patient consent waiver was obtained in order to
conduct this research. To be eligible for the study, patients were required to
have undergone both RHC and chest CT scan within a designated five year
period between November 18, 2003 and November 18, 2008. Additionally, no
more than six months was allowed between RHC and chest CT for patients to be
included. In the event that a patient had multiple RHCs over the five year period
indicated above, only the earliest RHC for which corresponding chest CT data
was available was included in the study. A single rheumatology fellow performed
electronic chart review to identify those patients meeting the American College of
Rheumatology (ACR) criteria for the diagnosis of SSc [19]. Exclusions were
made for patients whose chest CT showed signs of intubation or lung resection,
whose mediastinal vascular delineation was judged as poor or worse (See CT
Scoring Section), who had an insufficient number of image levels to determine
overall inflammatory and fibrotic lung involvement, and who received nitric oxide
prior to RHC.
For purposes of analysis, patients were divided into two groups based on
the absence (Group A) or presence (Group 8) of interstitial fibrosis on chest CT
(see below). A subset of patients with available pulmonary function tests (PFTs)
were also divided into groups based on forced vital capacity (FVC)
measurements. To be included in this subgroup analysis, patients were required
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to have PFTs within 3 months of chest CT. Patients with FVC > 70% predicted
(Group C) were compared to those with FVC < 70 predicted (Group D)

3.3.2 CT Scoring
All CT images incorporated into this study were initially reviewed by one
observer (J.R., with 15 years of radiologic experience) to determine the extent of
ILD. The same observer also graded each image according to the quality of
mediastinal vascular delineation. The extent of ILD was measured according to
a previously reported protocol [38] with slight variations. Ground glass opacity

=absent, 1 = less than 5% of
to 49% of total lung, 4 =50% to

(GGO) was evaluated using a six point scale (0

= up to 250/0 of total lung, 3 = 25%
75% of total lung, 5 =greater than 75% of total lung) as was interstitial fibrosis (0
= absent, 1 = interlobular septal thickening wlo honeycombing, 2 =
honeycombing involving up to 25% of total lung, 3 = honeycombing involving
from 250/0 to 490/0 of total lung, 4 = honeycombing involving from 500/0 to 750/0 of
total lung, 5 = honeycombing involving greater than 750/0 of total lung). Vascular
total lung, 2

delineation was rated using a Likert scale (1 = very poor, 2 = poor, 3 =
reasonable, 4

=good, 5 =very good)[7].

After eliminating all studies receiving a vascular delineation rating of less
than "reasonable", two observers (M.K. and L.H.) independently reviewed the
remaining images to measure the diameter of both the main pulmonary artery
and the aorta. Measurements were made using computer calipers with both
observers blinded to all clinical data regarding the research subjects. All images
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were viewed at mediastinal window settings (window width = 390 HU, window
level

= 60 HU) with the mediastinum zoomed to full screen.

The MPAD was

defined as the greatest distance perpendicular to the long axis of the vessel as it
passes anteroposteriorly across the base of the heart on supine full-chest
sequence. The widest diameter of the aorta was also measured at the same
scan level.

3.3.3 Right Heart Catheterization
In general, RHC was performed following the acquisition of right femoral
vein access using a 7 French introducer sheath. A 7 French Swan-Ganz balloon
tipped catheter was then introduced via the sheath and advanced through the
right heart chambers into the pulmonary capillary wedge position. PAPs and
pulmonary capillary wedge (PCW) pressures were recorded at rest for all
patients. Pulmonary vascular resistance (PVR) was calculated using the
following equation: PVR

=(mPAP-mPCW)/CO where mPAP is the mean

pulmonary artery pressure, mPCW is the mean pulmonary capillary wedge
pressure, and CO is the cardiac output measured by either Fick's method or
thermodilution.

3.3.4 Statistical Analysis
Categorical data are expressed as proportions while continuous variables
are characterized by mean (S.D.) if normally distributed or median (range) if
distributed otherwise. For continuous variables, comparisons between groups
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were made using the Student's t-test or Mann-Whitney U test depending on the
distribution of the data. Either the Chi-square test or Fisher's exact test was
used to compare categorical data between groups. Correlations were examined
using Pearson's coefficient for normal data and Spearman's coefficient if the
assumption of normality could not be upheld. Given the limited sample size in
this study, four of the following variables were chosen for incorporation into a
multivariable linear regression model of mPAP based on the highest univariate
correlations: age, gender, ethnicity, aortic diameter, body surface area, and
presence or absence of fibrosis on chest CT. In order to investigate any potential
interaction regarding the presence of interstitial fibrosis on chest CT and the
relationship between mPAP and MPAD, a separate term was incorporated into
the multivariable regression model. Receiver operating characteristic analysis
was performed to determine the diagnostic accuracy of the MPAD measurement
in predicting the presence of PH.
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3.4 RESULTS
3.4.1 Patient attributes
After screening our patient base for the previously specified inclusion and
exclusion criteria, 48 subjects remained for incorporation into this study. Table 1
contains demographic information as well as clinical data for Group A and Group
B. Data was available on a fraction of the patients with regard to several
variables including PFT results. Of the 48 patients with suspected scleroderma,
3 patients had undetermined connective tissue disease (UCTD), 1 patient had
mixed sine scleroderma /sarcoidosis, 37 patients met the ACR criteria for the
diagnosis of SSc, 2 patients met ACR criteria for SSc while also suffering from
concomitant lupus, and 5 patients had insufficient records to accurately
determine a diagnosis.

No significant difference existed between Group A and

Group B when considering CT-determined measurements of the mediastinal
vasculature and invasive measures of pulmonary hemodynamics. The average
MPAD in Group A was 31.3mm (S.D. 4.2mm) compared to 33.2mm (S.D.
4.6mm) in Group B (p = 0.15). Upon evaluation of pulmonary hemodynamics,
the average mPAP was found to be 27.5mmHg (C.1. 22.4-33.9mmHg) in Group A
and 30.9mmHg (C.1. 26.9-35.5mmHg) in Group B (p = 0.35). Forced vital
capacity data was available in 14 patients from Group A and 20 patients from
Group B with mean values of 85.90/0 predicted (S.D. 19.8% predicted) and 64.2%
predicted (S.D. 16.7% predicted) respectively (p = 0.002). Diffusion capacity for
carbon monoxide (DLeo) was also available in 14 patients in Group At but only
19 patients in Group B. Similar to FVC, a statistically significant difference in
OLeo was found between the groups with Group A having a mean value of 50.10/0
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predicted (C.I. 43.7-58.9% predicted) and Group B having a mean value of
33.9% predicted (C.1. 28.8-40.7% predicted) (p = 0.001).
Overall, 34 patients had available FVC data with Table 2 containing a
comparison of important patient characteristics between Group C and Group O.
The main differences between FVC-based groups pertain to patient age and
MPAO. The average age of patients in Group C was 61.7 years
years) compared to 52.5 years (S.D. 11.3 years) in Group 0 (p

(S.~.

11.7

=0.03).

On

average, MPAO was larger (p = 0.032) in Group 0 (33.0mm, S.D. 3.8mm) versus
Group C (30.1mm, S.D. 3.7mm).

3.4.2 Univariate correlations
Strong correlations between mPAP and MPAD were found in this study
regardless of the presence or absence of mild to moderate interstitial fibrosis on
chest CT (Table 3). The correlation coefficient between mPAP and MPAO in
Group A (r = 0.68, p

=0.001) was very close to the value of the correlation

coefficient found in Group B (r = 0.70, P < 0.0001) (See Figures below).
Interestingly, when categorizing patients based on FVC, the correlation between
mPAP and MPAD was substantially attenuated with Group C (r

=0.69, p =

=0.42, P =0.11) (See
Figures below). Significant correlations were also present in both Group A (r =
0.50, P = 0.03) and Group 8 (r = 0.47, P = 0.01) between mPAP and the ratio of
0.002) exhibiting a higher coefficient value than Group 0 (r

MPAO to aortic diameter (AD), though these values were somewhat less in
magnitude when compared to the correlation between mPAP and MPAD. In
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contrast, marked variation between Group A (r = 0.51, P =0.03) and Group B (r =
0.09, P = 0.67) can be seen when PVR is correlated with MPAD/AD. This
difference is lessened considerably when evaluating the relationship between
PVR and MPAD. When the relationship between mPAP and MPAD/AD was
evaluated in Group C and Group 0, a different pattern emerged than that seen
when dividing patients based on CT measurements of interstitial fibrosis. While
the correlation in Group C (r = 0.66, P = 0.003) remained similar to that seen
between mPAP and MPAD, Group D (r

=-0.09, p =0.73) showed no significant

correlation between mPAP and MPAD/AD. Group differences in the correlation
between invasive measures of pulmonary hemodynamics and PFT results can
also be appreciated from Table 3.

3.4.3 Multivariable linear regression
No relationship between mPAP and ethnicity, AD, or fibrosis group was
identified on multivariable linear regression with MPAD serving as the primary
measure of vascular dimension. Also, there was no interaction between MPAD
and the presence or absence of fibrosis using this model (~hat = 0.07, P = 0.43).

3.4.4 Diagnostic Accuracy
Utility of the MPAD measurement was accessed by generating a receiver
operating characteristic curve (See Figure below) and calculating the area under
the curve (AUC = 0.86). An MPAD value of 30.8 mm yielded the highest
sensitivity and specificity at 81.30/0 and 87.5% respectively.
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3.5 DISCUSSION
Frequently incorporated into the assessment of patients at risk for PH,
MPAD has been valued by both radiologist and clinicians as an important
indicator of elevated PAP with one study reporting a correlation coefficient as
high as 0.83 [8] between these two measures. Recent literature [11, 12] has
begun to challenge the previously identified relationship between mPAP and
MPAD in select populations.

Devaraj et al. [12] have demonstrated that no

correlation exists between mPAP measured by RHC (mPAPRHC) and MPAD in a
generalized population of patients suffering from diffuse pulmonary fibrosis. This
finding was initially reported in a more specific group of idiopathic pulmonary
fibrosis patients by Zisman et al. [11]. Perhaps most recently, the correlation
between mPAPRHC and MPAD has been evaluated in a limited group of SSc
patients with chest CT data gathered strictly under a pulmonary embolism
protocol [13]. We sought to further analyze the correlation between mPAPRHC
and MPAD in scleroderma patients using a diverse array of chest CT protocols.
The single prior study [13] concerning the correlation (r = 0.35, P = 0.002)
between mPAPRHC and MPAD in SSc patients initially evaluated this relationship
in a group of 81 patients regardless of the extent of IlD. The authors then
excluded patients with significant IlD, defined as either a disease extent> 20%
according to a high-resolution CT scoring system set forth by Goh et al. [43] or
FVC < 70% predicted on PFTs. The remaining subset of 63 patients exhibited a
correlation between mPAP RHC and MPAD (r = 0.57, P < 0.001) that was
noticeably superior to that seen in the original group of 81 patients. While these
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results demonstrate that higher levels of ILD attenuate the correlation between
mPAP RHC and MPAD, several questions remain unanswered. Which, if any, CTderived measures of ILD may account for this attenuation in correlation between
mPAPRHC and MPAD? Furthermore, what is the stability of this correlation in
patients with mild to moderate ILD on chest CT who may benefit most from
interventions made early in the course of disease?
One major difference between our study and that by Condliffe et al. [13] is
the method by which patients were categorized prior to analysis of the correlation
between mPAPRHC and MPAD. GGO is a more frequent finding in SSc than in
patients with other types of lung disease such as idiopathic pulmonary fibrosis
[44] and was highly prevalent in our sample. It is commonly thought that GGO
represents alveolar and interstitial inflammation while a reticular pattern and/or
honeycombing is more indicative of fibrosis [45-47]. Among the various
radiologic signs of ILD, mainly the interstitial fibrosis score has been shown to
correlate, if only weakly, with FVC [39]. With these issues in mind and when
considering the fact that the interstitial fibrosis score allowed for a more uniform
division of groups, we chose to primarily evaluate the role of this CT-derived
measure of ILD with regard to the previously described attenuation in the
correlation between mPAPRHC and MPAD. Our results show that the correlation
between mPAPRHC and MPAD is maintained despite the presence of mild to
moderate interstitial fibrosis on chest CT as represented by a fibrosis score of 3
or less.

Indeed, 75% of our patients with fibrosis (Group B) had a score of < 2,
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representing the moderate nature of this type of interstitial involvement (data not
shown).
Despite the discovery that CT-derived fibrosis score did not influence the
correlation between mPAPRHC and MPAD in our sample, an interesting finding
resulted when categorizing patients based on available PFT data. Values of FVC
< 70% predicted were associated with a considerably lower correlation (r

=0.42,

P = 0.11) between mPAPRHC and MPAD than values of FVC > 700/0 predicted
(r

=0.69, P =0.002).

One possible explanation for this difference in correlation

could be that the criterion of FVC < 70% predicted selects out patients with a
greater extent of disease on chest CT scan [43]. In fact, 37.5% of our population
with an FVC < 70% predicted also had a fibrosis score of 3. Thus, all but one
patient in our study with a fibrosis score of 3 was incorporated into Group D.
Notwithstanding this discrepancy in fibrosis score distribution when grouping
patients based on FVC, it is unlikely that the increase in CT-measured fibrosis is
responsible for the attenuation in correlation between mPAPRHC and MPAD seen
in Group D. This is evidenced by the finding that the correlation coefficient
between mPAPRHC and MPAD in patients with a fibrosis score of 3 (r

= 0.71,

P =0.07) is relatively strong and trends toward statistical significance in spite of
an extremely low sample size (See Figure below). Therefore, to reiterate the
finding from above, the appearance of fibrosis involving up to 50% of the lungs
on CT does not influence the correlation between mPAPRHC and MPAD in
scleroderma patients. The revelation that FVC attenuates this correlation may
reflect the relatively weak association between CT-measured pulmonary fibrosis
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and clinically available measurements of lung function in this population [39].
Contrary to multiple prior studies [7, 12, 13], we did not find MPAD/AD to
strengthen the correlation with mPAPRHC in any group. MPAD/AD was most
noticeably inferior to MPAD as a correlate of mPAPRHC in Group D. Group D also
exhibited significantly larger MPAD values than Group C with no difference in AD
or mPAP between the groups. When combined, these factors point to
mediastinal traction [7, 11, 42] as a possible explanation for the poor
performance of MPAD/AD in Group D, however, concomitant systemic arterial
disease may also contribute as such patients were not excluded from this study.
This study has several limitations including a patient sample that was
gathered solely from a tertiary care center. Another major limitation was the lack
of available PFT data for 14 of the 48 patients in this study. Therefore, subjects
with PFT data may represent a subset of patients with more severe disease. In
addition, patients were grouped for analysis based primarily on CT-derived
measurements of fibrosis alone. As discussed earlier, this grouping was
necessary in order to isolate the contribution of fibrosis to the attenuation in
correlation between MPAD and mPAP RHC . The interval between RHC and chest
CT was another potential limitation to this study, although, up to 9 months
between tests has been reported in the literature [12].
In summary, this study suggests that the presence of fibrotic lung disease
on chest CT scan does not influence the correlation between mPAP RHC and
MPAD in scleroderma patients with mild to moderate degrees of total pulmonary
involvement. On the other hand, categorizing patients according to FVC may
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identify those in whom MPAD is a poor predictor of mPAPRHC. Currently
available clinical algorithms, such as that proposed by Goh et al. [43] and further
exploited by Condliffe et al.[13], may be useful for predicting overall morbidity
and mortality in SSc, but limited in utility when assessing morbidity related to PH
in this complex and protean disease. Algorithms of this nature may be
excessively stringent if used to evaluate suspected PH, thereby resulting in the
avoidance of MPAD measurements from patients with higher levels of pulmonary
fibrosis on chest CT.

Finally, with a positive predictive value approaching 930/0

in this study, the measurement of MPAD on chest CT may hold future promise in
avoiding unnecessary RHC and contribute to PH screening when incorporated in
composite scoring systems [13] that enhance the negative predictive value of this
measure.
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Table 1: Patient Characteristics by Fibrosis Group
Variable
Gender, %
female

N(Group A:B)

Total

Group A

Group B

P-value

20:28

81.3

80.0

82.1

1.00*

13:19

68.8

84.6

57.9

0.14*

Limited: Diffuse,
%

PAH, % of mPAP
~ 25 with pew ~

15

Data analyzed using the following: ¥Student's t-test, *Fisher's Exact test, Chi-Square, €Wilcoxin Rank-Sum
nVariable was log-transformed. Data represented as antilog of mean (confidence interval).
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Table 2: Patient Characteristics by FVC Group

Variable

Gender, %
female

Total

Group C

Group 0

P-value

73.5

77.8

68.8

0.7*

Data analyzed using the following: ¥Student's t-test, *Fisher's Exact test
nVariable was log-transformed. Data represented as antilog of mean (confidence interval).
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Table 3: Univariate Correlations

Variables
MPAO
mPAP RHC

PVR

MPAO/BSA
mPAP RHC
PVR

Group A

Group B

0.68
0.62

0.001
0.01

0.7
0.49

<0.0001
0.01

0.45*
0.49

0.05
0.04

0.59*
0.54

0.001
OJ)()4

-0.63
-0.51

0.02
0.09

-0.08
-0.004

0.75
0.99

w

en

OleoH, % predicted
mPAP RHC

PVR

mPAP RHc was log-transformed for all univariate correlations.
*Spearman's correlation coefficient.
rvariable was log-transformed in addition to mPAPRH:-

GroupC

0.69

0.001

0.42

0.11

Figure 1: Demonstration of MPAD Measurement on Axial CT Image
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